Abstract
A tough review of the state of the art in gene therapy has concluded that the technology has been oversold, there are few unambiguous examples in which patients have benefited from the technique, and the National Institutes of Health has supported too many clinical trials that are of limited scientific value. The bottom line: More research is needed to improve basic gene transfer techniques. (Report is available from the World Wide Web at http://www.nih.gov/news/panelrep.html).

This publication has 2 references indexed in Scilit: